Journal of Bioequivalence & Bioavailability

Abstract

Bioequivalence Evaluation of a Combine Formulation of Pioglitazone/ Metformin in Healthy Pakistani Volunteers

Mateen Abbas, Sualeha Riffat, Abdul Muqeet Khan and Muhammad Nawaz

The purpose of this study was to evaluate bioequivalence of a combine formulation of pioglitazone/metformin 15/850 mg tablet with those of an established branded formulation. An open-label, single-dose, randomized, 2-way crossover study was conducted in fasted healthy Pakistani male volunteers. The concentrations of pioglitazone and metformin in plasma were analyzed by reverse phase High Performance Liquid Chromatography (HPLC). The plasma concentration-time curves were used to obtain pharmacokinetic parameters including AUC 0-t , AUC 0-∞ , and C max . The formulations were considered bioequivalent if the 90% confidence intervals (CIs) for AUC, and C max fell within the interval of 80% to 125%, declared in bioequivalence guidelines. On analysis of variance, no period, formulation or sequence effects were observed for any pharmacokinetic property. The 90% confidence intervals of pioglitazone for the geometric mean ratios of C max , AUC 0-t and AUC 0-∞ were 93.34% to 103.12%, 86.15% to 106.03% and 85.62% to 107.41%, respectively. Similarly, the 90% CIs of metformin for the geometric mean ratios of C max , AUC 0-t and AUC 0-∞ were 87.64% to 100.85%, 86.68% to 116.15 and 94.14% to 122.71%, respectively, qualifying the predetermined criteria for bioequivalence based on the rate and extent of absorption.